Novartis: data shows new multiple sclerosis drug is efficien
(CercleFinance.com) - Novartis' experimental siponimod's has showed its efficacy on disability and cognition in secondary progressive multiple sclerosis, according to new analyses released on Friday.
Novartis today announced results from a phase III study showing that siponimod consistently reduced the risk of confirmed disability progression in SPMS patients, with and without relapses.
In addition, siponimod also showed a significant benefit on cognitive processing speed, the key cognitive function impacted by multiple sclerosis, which frequently deteriorates in people with the disease.
These results will be presented at the American Academy of Neurology (AAN) Annual Meeting, in Los Angeles, which starts tomorrow.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Novartis today announced results from a phase III study showing that siponimod consistently reduced the risk of confirmed disability progression in SPMS patients, with and without relapses.
In addition, siponimod also showed a significant benefit on cognitive processing speed, the key cognitive function impacted by multiple sclerosis, which frequently deteriorates in people with the disease.
These results will be presented at the American Academy of Neurology (AAN) Annual Meeting, in Los Angeles, which starts tomorrow.
Copyright (c) 2018 CercleFinance.com. All rights reserved.